Small-cell lung cancer (SCLC) is an aggressive neuroendocrine tumor often characterized by high relapse rates and a poor prognosis. Currently, clinicians face limited treatment options for patients who do not respond to standard chemotherapy. However, recent advancements in DLL3 CAR-T cell therapy offer a new beacon of hope. Researchers have identified Delta-like ligand 3 (DLL3) as a highly specific target because SCLC cells overexpress it, while healthy tissues generally do not.

Evaluating DLL3 CAR-T Cell Therapy in Preclinical Models

In this latest study, researchers used alpacas to develop unique antibody fragments known as variable domains of heavy-chain-only antibodies (VHH). These VHH-based constructs provide superior stability and affinity compared to traditional single-chain variable fragments (ScFv). Consequently, the team humanized the 1-B12 sequence to maximize therapeutic efficacy while minimizing potential immune reactions in humans. These humanized cells demonstrated robust cytokine secretion and powerful cytotoxic activity against SCLC cells during in vitro assays.

Furthermore, the study extended these findings to in vivo models. The DLL3 CAR-T cell therapy effectively suppressed tumor growth and significantly improved survival outcomes in these models. These results highlight the potential of VHH-based CAR T cells as a clinical candidate for patients with DLL3-positive tumors. Importantly, the strategy used to develop these specific antibodies could serve as a blueprint for targeting other difficult-to-treat solid tumors. Therefore, this research paves the way for future clinical trials focusing on neuroendocrine malignancies.

Frequently Asked Questions

What makes DLL3 a promising target for SCLC?

DLL3 is an ideal target because it is highly expressed on the surface of most small-cell lung cancer cells but remains largely absent in normal, healthy adult tissues. This differential expression allows therapies like CAR T cells to selectively destroy cancer cells while sparing healthy organs.

Why are VHH-based CAR T cells considered superior to ScFv?

VHH antibodies, derived from heavy-chain-only antibodies, are smaller and more structurally stable than traditional ScFv fragments. This compact size allows for better tumor penetration and higher binding affinity, which can lead to enhanced antitumor efficacy in complex solid tumor environments.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. Always consult with a qualified healthcare provider for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.

References

Guo H et al. VHH-based CAR-T cells targeting DLL3 show high efficacy in small-cell lung cancer models. Mol Cancer Ther. 2026 Feb 12. doi: 10.1158/1535-7163.MCT-25-0965. PMID: 41676850.

Owen DH, et al. DLL3: an emerging target in small cell lung cancer. J Hematol Oncol. 2019;12(1):61.